Biomedicine · global
Tree Frog Gut Bacteria Made Tumors Disappear in Mice, but Live Bacterial Cancer Therapy Remains Before the Early Threshold
A natural bacterium from the gut of the Japanese tree frog showed rare strength in a mouse model of colorectal cancer; it suggests that live bacterial therapies may not only adjust the gut microbiota, but also directly enter the tumor battlefield.
Cancer treatment is taking another look at microbes. In the past, gut bacteria were mostly regarded as background factors that influence responses to immunotherapy; this new study instead pushes a live bacterium to the front line, allowing it to reach tumors through the bloodstream, proliferate inside tumors, and trigger an immune attack at the same time. If the results can be extended by follow-up research, it would represent a path different from traditional chemotherapy, targeted drugs, and immune checkpoint inhibitors.
A team from the Japan Advanced Institute of Science and Technology isolated 45 bacterial strains from the guts of Japanese tree frogs, salamanders, and lizards, and screened them one by one for anticancer activity. The strongest performer was a bacterium called Ewingella americana. The study was published in Gut Microbes. Its focus was not on reshaping the overall gut microbiota, but on culturing a single strain and delivering it by intravenous injection into mice bearing colorectal cancer tumors.
According to the study abstract, after a single injection of E. americana, the mice’s colorectal tumors showed a complete response; in that model, the proportion of tumors cleared reached 100%. The research team also said that, in comparative experiments, the treatment outperformed control therapies such as anti-PD-L1 antibody and liposomal doxorubicin. However, these are still results from an animal model and cannot be directly inferred as efficacy in humans, nor can they be regarded as a ready-made cancer treatment.
What makes this bacterium notable is that it does not appear to work through a single mechanism alone. E. americana is a facultative anaerobe, able to grow in both oxygenated and hypoxic environments; solid tumors often contain hypoxic regions, which happen to provide space for bacterial expansion. The study indicated that within 24 hours after injection, the bacteria increased substantially inside tumors and caused direct damage to cancer cells.
Another layer of action came from the immune system. After the bacteria entered tumors, they attracted T cells, B cells, and neutrophils to gather, alongside increases in inflammatory signals such as TNF-alpha and IFN-gamma, shifting the tumor microenvironment from immune silence toward an attacking state. The researchers also proposed that tumor vascular leakage, the hypoxic environment, CD47 signals on the surface of cancer cells, and metabolic changes may together explain why the bacteria tended to concentrate in tumors rather than normal organs.
Safety remains one of the hardest problems for live bacterial therapies to overcome. This mouse study showed that the half-life of E. americana in blood was about 1.2 hours and that it was undetectable within 24 hours; organs such as the liver, spleen, lungs, kidneys, and heart showed no persistent colonization, inflammatory responses also receded within 72 hours, and 60 days of follow-up showed no signals of chronic toxicity. These data provide early confidence, but more assessment of dose, strain stability, infection risk, and immune side effects will still be needed before human trials.
The next step will determine whether this finding is an elegant animal experiment or can gradually move toward drug development. The research team plans to test other solid tumors, including breast cancer, pancreatic cancer, and melanoma, and will also explore the possibilities of divided dosing, intratumoral injection, and combinations with chemotherapy or immunotherapy. The truly critical question is whether this bacterium from the gut of an amphibian can maintain selective, controllable, and sufficiently safe anticancer effects in human tumors that are more complex and more heterogeneous.